Please assess the completion status of the following clinical trial:

Trial Title: Study of ONO-4538 in Unresectable Advanced or Recurrent Gastric Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men \& women ≥20 years of age~* Unresectable advanced or recurrent gastric cancer (including esophagogastric junction cancer)~* Histologically confirmed adenocarcinoma~* Refractory to or intolerant of standard therapy~* ECOG Performance Status score 0 or 1~* A life expectancy of at least 3 months~Exclusion Criteria:~* Current or past history of severe hypersensitivity to any other antibody products~* Patients with multiple primary cancers~* Patients with any metastasis in the brain or meninx that is symptomatic or requires treatment~* Patients with active, known or suspected autoimmune disease

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ONO-4538 Arm (Type: EXPERIMENTAL): ONO-4538 3 mg/kg solution intravenously every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
- Placebo Arm (Type: PLACEBO_COMPARATOR): Placebo intravenously every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends

Based on this trial design, predict the completion outcome and termination type (if applicable).